Category: Multiple Sclerosis

IMR International Limited, developers of e-communication and clinical information solutions, announced the launch of a comprehensive guide to Multiple Sclerosis (MS) within its new public health portal; http://www.epgpatientdirect.org. Supported by Merck Serono, the

Scientists in Scotland may be on the way to discovering the cause of long term disability in people with multiple sclerosis (MS). New research carried out at the University of Aberdeen in Scotland, led by Professor Chris Linington, showed that some people with MS have specific antibodies (a type of immune molecule) which attack nerve fibres. The newly identified antibodies recognise and attack a protein called neurofascin-186 which makes up part of the nerve fibre.

Genzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).

MS sufferers, who have found little benefit from drug treatments, are finding success in a diet that targets five food triggers. Sugar and saturated fats also contribute to the disease process. By identifying and eliminating food sensitivities, along with other simple dietary changes, the MS Recovery Diet can halt and reverse symptoms for those afflicted with MS.

Defects on cell-surface sugars may promote the short-term inflammation and long-term neurodegeneration that occurs in the central nervous system of multiple sclerosis patients, according to University of California, Irvine researchers.The findings also suggest that a dietary supplement similar to glucosamine may be useful as an oral therapy to correct these defects and to treat both the short-term and the long-term symptoms of the disease.

UroToday.

From JRRD Vol. 44, Issue 4Does the RT3 accelerometer spell the end of pen-and-paper questionnaires?Here is a great thoughtâ?¦the arduous task of filling out boring questionnaires may soon be obsolete! Well, at least for people with multiple sclerosis (MS) whose activity levels must be monitored by doctors.

The MS Society is delighted to announce that it has been highly commended for its publication MS Essentials 17: Pain and Sensory Symptoms at the British Medical Association’s Patient Information Book Awards in London. The award-winning MS Essentials series is produced in conjunction with people directly affected by multiple sclerosis (MS) and gives information on a wide range of issues relevant to the condition.

People with multiple sclerosis who stop taking the drug natalizumab may experience a rebound increase in disease activity, according to a study published September 12, 2007, in the online edition of Neurology, the medical journal of the American Academy of Neurology. The study involved 21 people who had MRI scans of their brains taken before taking natalizumab and again an average of 15 months after receiving the last infusion of the drug.

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) welcome the recent announcement by the Scottish Medicines Consortium (SMC) advising the use of TYSABRI® (natalizumab) in people with highly active relapsing remitting multiple sclerosis (RRMS).